Audrai O'Dwyer

We’re attending CPhI 2022 Frankfurt

We’re attending CPhI 2022 at Messe Frankfurt 1st – 3rd November ensure to visit our stand Hall 121 Stand A130 or contact us via skpharmteco@sk.com to arrange a face to face meeting before schedules book up. We look forward to connecting with you!

SK pharmteco’s HPAPI Robust Safety Controls Article in Specialty Chemicals Magazine

Safety First, Quality Always isn’t just a tag line for SK pharmteco and its business units; learn about our High Potency API manufacturing capabilities and robust safety controls both at AMPAC Fine Chemicals an SK pharmteco Company and at our sister site SK biotek Ireland an SK pharmteco Company with an article written by SK …

SK pharmteco’s HPAPI Robust Safety Controls Article in Specialty Chemicals Magazine Read More »

SK pharmteco announces $35m investment in Phase 1 of new expansion plan for SK biotek Ireland’s Swords Campus

SK pharmteco announces $35m investment in Phase 1 of new expansion plan for SK biotek Ireland’s Swords Campus SK pharmteco (SKPT) a global CDMO, part of SK Inc., is pleased to announce $35m investment for the initial phase of an expansion plan for SK biotek Ireland’s Dublin-based pharmaceutical manufacturing plant. This project will provide a …

SK pharmteco announces $35m investment in Phase 1 of new expansion plan for SK biotek Ireland’s Swords Campus Read More »

ChemistryToday C&G Therapy Article by Brian Mullan Head of Development & Innovation

In February’s issue ChemistryToday Brian Mullan Yposkesi’s Head of Development & Innovation has published an article on how C&GT are a fast growing and promising class of medicines, that offer the possibility of curing conditions with a genetic basis, that have few or no other options for patients. Click here to read Brian’s article: https://www.teknoscienze.com/wp-content/uploads/2022/02/Mullan_CO1_2022.pdf

Scroll to Top